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Critical weight loss is a major prognostic
indicator for disease-specific survival in
patients with head and neck cancer receiving
radiotherapy
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Background: Pre-treatment weight loss (WL) is a prognostic indicator for overall survival (OS) in head and neck cancer (HNC)
patients. This study investigates the association between WL before or during radiotherapy and disease-specific survival (DSS) in
HNC patients.
Methods: In 1340 newly diagnosed HNC patients, weight change was collected before and during (adjuvant) radiotherapy with
curative intent. Critical WL during radiotherapy was defined as 45% WL during radiotherapy or 47.5% WL until week 12.
Differences in 5-year OS and DSS between WL groups were analysed by Cox’s regression with adjustments for important
socio-demographic and tumour-related confounders.
Results: Before radiotherapy, 70% of patients had no WL, 16% hadp5% WL, 9% had45–10% WL, and 5% had410% WL. Five-
year OS and DSS rates for these groups were 71%, 59%, 47%, and 42% (Po0.001), and 86%, 86%, 81%, and 71%, respectively
(Po0.001). After adjustment for potential confounders, 410% WL before radiotherapy remained significantly associated with a
worse OS (HR 1.7; 95% CI 1.2–2.5; P¼ 0.002) and DSS (HR 2.1; 95% CI 1.2–3.5; P¼ 0.007). The 5-year OS and DSS rates for patients
with critical WL during radiotherapy were 62% and 82%, compared with 70% and 89% for patients without critical WL (P¼ 0.01;
P¼ 0.001). After adjustment, critical WL during radiotherapy remained significantly associated with a worse DSS (HR 1.7; 95% CI
1.2–2.4; P¼ 0.004).
Conclusion:Weight loss both before and during radiotherapy are important prognostic indicators for 5-year DSS in HNC patients.
Randomised studies into the prognostic effect of nutritional intervention are needed.
Patients with head and neck cancer are predominantly at risk for
malnutrition due to anorexia, sequelae of the treatment that hamper
food intake (e.g., xerostomia or dysphagia) and metabolic alterations
as a result of inflammation, which can be induced by the tumour or
the therapy (Van Cutsem and Arends, 2005; Baracos, 2006; Richey
et al, 2007; Silver et al, 2007). Malnutrition is a subacute or chronic
state in which a combination of varying degrees of undernutrition
and inflammatory activity has led to a change in body composition
and diminished function (Soeters et al, 2008). Weight loss is one of
the main symptoms of malnutrition.
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Weight loss is a frequently observed problem among patients
with head and neck cancer (Jager-Wittenaar et al, 2007; Ehrsson
et al, 2010). Malnutrition before treatment may be seen in as high
as 63% of patients, and its prevalence is associated with the
location of the tumour (Nayel et al, 1992; Argiris et al, 2004; Unsal
et al, 2006; Jager-Wittenaar et al, 2007; Capuano et al, 2010, 2008;
Langius et al, 2010). During treatment, many patients develop
treatment-related toxicities, of which dysphagia caused by
mucositis is one of the most prominent. These acute toxicities
result in discomfort and difficulties with eating. During radio-
therapy, the prevalence of malnutrition rises to 41–88% (Nayel
et al, 1992; Unsal et al, 2006; Langius et al, 2010). Sequelae of
radiation therapy and weight loss may continue for several weeks
after completion of radiotherapy (Langius et al, 2010; Mehanna
et al, 2010).
It has been demonstrated that weight loss before treatment is a
prognostic indicator for overall survival (Brookes, 1985; Pugliano
et al, 1999; Van Bokhorst-de van der Schueren et al, 1999; Nguyen
and Yueh, 2002; De Cassia Braga et al, 2003; Argiris et al, 2004;
Van Den Broek et al, 2004; Pedruzzi et al, 2008).
As the association between weight loss before or during
radiotherapy and disease-specific survival in patients with head
and neck cancer is unclear, we set out to investigate this.
MATERIALS AND METHODS
Study population. A consecutive cohort of head and neck cancer
patients treated by radiotherapy between January 2000 and
January 2009 (n¼ 1799) was investigated for inclusion in this
study. Main inclusion criterion was curative radiotherapy, either
as sole treatment (with or without chemotherapy) or post-
operatively. Patients younger than 18 years, patients with a
tumour of the ear, skin, or oesophagus, and those with previous
cancer history were excluded (Figure 1). The final study
population was composed of 1340 patients. This study was
approved by the Medical Ethics Committee of the VU University
Medical Center Amsterdam.
Radiotherapy. All patients were treated on 6-MV linear accel-
erators (Varian Medical Systems, Inc., Palo Alto, CA, USA),
immobilised in the supine position by the use of individually
designed facial masks. From January 2000, conventional three-
dimensional conformal radiotherapy was applied until the clinical
introduction of parotid gland sparing IMRT in October 2004. In
the primary irradiated patients, the tumour and lymph-node
metastases were treated with 2Gy per fraction up to a total dose of
70Gy. A dose of 46Gy in daily fractions of 2Gy (or an equivalent
dose of 35 daily fractions of 1.55Gy) was given to the elective nodal
areas. Patients treated with postoperative radiotherapy received 2-
Gy daily fractions at the primary site and nodal metastases to a
total dose of 56 or 66Gy, depending on the surgical margin status
and the presence of extranodal spread. Again the elective dose was
46Gy in 2-Gy daily fractions (or an equivalent dose of 28 fractions
of 1.8Gy or 33 fractions of 1.65Gy). In the case of concomitant
chemoradiation, three cycles of cisplatin 100mgm 2 were given
on days 1, 22, and 43.
From the start of radiotherapy, patients received dietary
counselling to achieve individual nutritional requirements. If
nutritional requirements could not be reached by regular food
products, then energy-enriched oral nutritional supplements and/
or enteral tube feeding by nasogastric tube or percutaneous
endoscopic gastrostomy were subscribed.
Data collection. All data were prospectively collected. At baseline,
patient and tumour characteristics were recorded. Weight loss
before radiotherapy was recalled by the radiotherapist and, based
on the equation (current weight usual weight)/usual
weight 100%, categorised into four groups: no weight loss,
p5% weight loss, 45–10% weight loss and 410% weight loss.
Body weight was measured at the start of radiotherapy (±7 days)
and weekly thereafter until the eighth week, and at 12 weeks after
the start of radiotherapy (labelled as ‘during radiotherapy’). Body
weight was measured by wearing light indoor clothing and shoes
on a digital electronic scale (Seca (Hamburg, Germany), Alpha
770) to the nearest 0.1 kg. Weight was corrected for clothing and
shoes by subtracting 2.0 kg for men and 1.3 kg for women (Frank
and Dunlop, 2000).
Tumour of the ear, skin, or
oesophagus (n =63)
Pre-radiotherapy weight loss
Excluded based on missing data (n =34)
Weight loss during radiotherapy
Excluded based on missing data (n =172)
Analysed (n =1306)
Total cohort (n =1340)
Palliative treatment or previous history 
of cancer (n =379)
< 18 years (n =3)
Missing data on both weight loss
variables (n =14)
Excluded (n =459)
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Definitions. Critical weight loss was defined as body weight loss
of45% from the start of radiotherapy until week 8 or47.5% until
week 12 according to the international consensus statement (White
et al, 2012). Because we earlier observed that acute radiotherapy
induced toxicity and weight loss arise after 2 weeks of radiotherapy
(Langius et al, 2010), the time span for critical weight loss during
radiotherapy was expected to be the last month of radiotherapy.
Overall survival was defined as the time elapsed between the
start of radiotherapy and the date of death of any cause, or if the
patient was still alive, and 5 years after the start of radiotherapy.
Disease-specific survival was defined as the time elapsed between
the start of radiotherapy and the date of death due to cancer, or if
the patient was still alive, and 5 years after the start of radiotherapy.
Patients who were lost to follow-up within 5 years were censored at
their last date of follow-up. In the analysis of disease-specific
survival, deaths due to causes other than head and neck cancer
were treated as censored observations at the time of death.
Statistical analysis. To test differences in patient, tumour, and
treatment characteristics between survivors and non-survivors, w2
tests were used regarding gender, tumour location, TNM stage
(Edge et al, 2010), baseline WHO performance score, weight loss
before radiotherapy, treatment modality, and radiotherapy on the
neck nodes, and independent t test was used regarding age.
Survival curves were generated using the method of Kaplan–
Meier. The log-rank test was used to examine the difference in
overall and disease-specific survival between weight loss groups.
Cox’s proportional hazard models were used to build multivariate
(i.e., adjusted) models. Relevant factors influencing both weight
loss and the survival period were selected a priori, based on the
literature. Potential confounder variables for the association
between weight loss before radiotherapy and overall and disease-
specific survival were age, gender, tumour location (oral cavity,
oropharynx, nasopharynx, hypopharynx, larynx, nasal cavity and
paranasal sinuses, major salivary glands, and unknown primary),
TNM stage (I, II, III, and IV), prior head and neck surgery, and
baseline WHO performance score (0, 1, and 2/3). For the
association between weight loss during radiotherapy and overall
and disease-specific survival, we additionally adjusted for weight
loss before radiotherapy (no weight loss, p5% weight loss,
45–10% weight loss, and 410% weight loss), treatment modality
(RT alone, RTþ surgery, and RTþ chemotherapy±surgery), and
radiotherapy on the neck nodes (none, unilateral, and bilateral).
We attempted to adjust for comorbidity by the Adult Comorbidity
Evaluation-27 (ACE-27) test (Paleri and Wight, 2002), but the
scores were available only in patients receiving chemoradiotherapy.
Therefore, a subgroup analyses was performed to analyse the effect
of comorbidity on the association between weight loss and overall
and disease-specific survival.
Interaction between weight loss and gender or age with respect
to overall and disease-specific survival was investigated, but both
were no effect modifiers. Proportional hazard assumptions for each
model was investigated and confirmed by testing the constancy
over time of the log-hazard ratio for each model. P-values ofo0.05
were considered as statistically significant. Analyses were per-
formed using the SPSS software (version 20.0.0; 2011 IBM
Corporation, New York, NY, USA).
RESULTS
The majority of patients (70%) were male. The mean age was
61.4±12.0 years, and ranged from 19 to 96 years. Tumours were
mainly located at the larynx and oropharynx. Eighteen percent of
patients had stage I tumours, 21% stage II, 18% stage III, whereas
43% had stage IV tumours. Slightly more than half of the patients
received a combined modality treatment (Table 1).
Four-hundred and seventy-one patients (35%) died within 5
years. No significant difference was found between the survivors
and the non-survivors regarding gender. There were significant
differences between the survivors and the non-survivors regarding
age, tumour location, TNM stage, weight loss before radiotherapy,
WHO performance score, treatment modality, and radiotherapy
on the neck nodes (Table 1).







1340 (100) 869 (65) 471 (35)
Gender
Male 937 (70) 595 (64) 342 (36) 0.11
Female 403 (30) 274 (68) 129 (32)
Age
Mean (s.d.) 61.4±12.0 60.0±11.7 64.1±12.1 o0.001
Tumour location
Oral cavity 242 (18) 140 (58) 102 (42) o0.001
Oropharynx 310 (23) 189 (61) 121 (39)
Nasopharynx 47 (4) 33 (70) 14 (30)
Hypopharynx 74 (6) 22 (30) 52 (70)
Larynx 436 (33) 321 (74) 115 (26)
Nasal cavity and
paranasal sinuses
106 (8) 77 (73) 29 (27)
Major salivary glands 75 (6) 53 (71) 22 (29)
Unknown primary 50 (4) 34 (68) 16 (32)
TNM stage
I 232 (18) 193 (83) 39 (17) o0.001
II 269 (21) 206 (77) 63 (23)
III 232 (18) 159 (68) 73 (32)
IV 550 (43) 267 (48) 283 (52)
Weight loss before RT
None 911 (70) 642 (71) 269 (30) o0.001
p5% 215 (16) 126 (59) 89 (41)
45–10% 111 (9) 52 (47) 59 (53)
410% 69 (5) 29 (42) 40 (58)
WHO performance score
0 399 (38) 305 (76) 94 (24) o0.001
1 533 (51) 333 (63) 200 (37)
2/3 116 (11) 44 (38) 72 (62)
Treatment modality
RT alone 591 (44) 403 (68) 188 (32) 0.01
SurgeryþRT 485 (36) 313 (65) 172 (35)
ChemoRT 251 (19) 143 (57) 108 (43)
SurgeryþChemoRT 13 (1) 10 (77) 3 (23)
RT dose
Median 68 68 70 0.09
RT on the neck nodes
No 350 (26) 275 (79) 75 (21) o0.001
Unilateral 225 (17) 162 (72) 63 (28)
Bilateral 762 (57) 432 (57) 330 (43)
Abbreviations: RT¼ radiotherapy; s.d.¼ standard deviation; TNM¼ tumour, node, metastasis;
WHO¼world health organisation. P-valueso0.05 are shown in bold. P-values were obtained
by independent t-test or w2 tests.
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Weight loss before radiotherapy. Before radiotherapy, 70% of
patients had no weight loss, 16% had p5% weight loss, 9% had
45–10% weight loss, and 5% had 410% weight loss (Table 1).
Five-year overall survival rates for these groups were 71%, 59%,
47%, and 42%, respectively (log rank: Po0.001; Figure 2). Five-
year disease-specific survival rates for these groups were 86%, 86%,
81%, and 71%, respectively (log rank: Po0.001).
The unadjusted Cox’s regression analysis (Table 2) showed that
weight loss before radiotherapy (of any category) was significantly
associated with a worse overall survival. In addition, we found that
the two most severe weight loss categories (45–10% and 410%
weight loss) were significantly associated with a worse disease-
specific survival. After adjustment for all previously mentioned
potential confounders, 410% weight loss before radiotherapy
remained significantly associated with a worse overall (HR 1.7; 95%
CI 1.2–2.5; P¼ 0.002) and disease-specific survival (HR 2.1; 95%
CI 1.2–3.5; P¼ 0.007) (Table 2).
In the subgroup of chemoradiotherapy, comorbidity nearly
affected the association between weight loss before chemora-
diotherapy and overall survival (410% weight loss HR 3.3, 95% CI
1.7–6.7, P¼ 0.001; 45–10% weight loss HR 2.3, 95% CI 1.3–4.2,
P¼ 0.005; p5% weight loss HR 1.8; 95% CI 1.0–3.2; P¼ 0.041).
Comorbidity was not significantly associated with disease-specific
survival.
Weight loss during radiotherapy. Critical weight loss during
radiotherapy was observed in 57% of patients. Mean weight loss
during radiotherapy was 4.1 (±4.7) kg, which corresponded to 5.4
(±6.1)% of body weight. On average, patients with critical weight
loss lost 9.0 (±4.8)% of their body weight.
Patients with critical weight loss had lower 5-year overall
survival rates than patients without critical weight loss during
radiotherapy (survival rates: 62% vs 70%; log rank: P¼ 0.01).
However, the adjusted association was no longer statistically
significant (HR 1.1; 95% CI 0.9–1.4; P¼ 0.295) (Table 3).
The 5-year disease-specific survival rate for patients with critical
weight loss was 82%, compared with 89% for patients without
critical weight loss (HR 1.7; 95% CI 1.2–2.3; P¼ 0.001; Figure 3).
After adjustment for all confounders, disease-specific survival was
still significantly worse for patients with critical weight loss during
radiotherapy (HR 1.7; 95% CI 1.2–2.4; P¼ 0.004) (Table 3).
In the subgroup of chemoradiotherapy, all patients who died
because of head and neck cancer had critical weight loss during
therapy. Therefore, no further subgroup analyses were possible.
Patients who were excluded because of missing baseline weight
(Figure 1), had a shorter overall survival time compared with the
included patients (log rank: P¼ 0.009). Disease-specific survival
was not significantly different.
DISCUSSION
Weight loss as a consequence of (chemo)radiotherapy is a common
problem in patients with head and neck cancer (Langius et al,
2013). However, little is known about its prognostic effect on
disease-specific survival. This study shows that critical weight loss
during radiotherapy is independently associated with a 1.7 times






























Figure 2. Kaplan–Meier survival plot of overall survival by weight loss
category before radiotherapy (log-rank test: Po0.001).
Table 2. Cox regression analyses of the association between weight loss
before radiotherapy and 5-year overall and disease-specific survival
Crude model Adjusted modela
HR (95% CI) P-value HR (95% CI) P-value
Overall survival
p5% WL 1.6 (1.3–2.0) o0.001 1.1 (0.9–1.4) 0.388
45–10% WL 2.3 (1.7–3.0) o0.001 1.4 (1.2–1.9) 0.026
410% WL 3.1 (2.2–4.3) o0.001 1.7 (1.2–2.5) 0.002
Disease-specific survival
p5% WL 1.1 (0.8–1.7) 0.570 0.9 (0.6–1.4) 0.647
45–10% WL 1.7 (1.1–2.7) 0.021 1.3 (0.8–2.1) 0.333
410% WL 3.3 (2.1–5.3) o0.001 2.1 (1.2–3.5) 0.007
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; WL¼weight loss;
TNM¼ tumour, node, metastasis; WHO¼world health organisation. P-values o0.05 are
shown in bold.
aAdjusted for age, gender, tumour location, TNM stage, prior head and neck surgery, and
WHO performance score.
Table 3. Cox regression analyses of the association between critical
weight loss during radiotherapy and 5-year overall and disease-specific
survival
Crude model Adjusted modela
HR (95% CI) P-value HR (95% CI) P-value
Overall survivalb 1.3 (1.1–1.6) 0.010 1.1 (0.9–1.4) 0.295
Disease-specific
survivalb
1.7 (1.2–2.3) 0.001 1.7 (1.2–2.4) 0.004
Abbreviations: CI¼ confidence interval; HR¼hazard ratio; TNM, tumour, node, metastasis;
WHO¼world health organisation. P-values o0.05 are shown in bold.
aAdjusted for age, gender, tumour location, TNM stage, WHO performance score, weight
loss before radiotherapy, radiotherapy on the neck nodes and treatment modality.
bNo critical weight loss vs critical weight loss (45% weight loss from the start of
radiotherapy until week 8 and/or 47.5% until week 12).
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Moreover, this large study demonstrates that weight loss before
radiotherapy is also independently associated with almost two-fold
risk of dying.
The association between pre-treatment weight loss and disease-
specific survival has been investigated only once in a subgroup of
patients with head and neck cancer (Regueiro et al, 1994). In that
study, weight loss before radiotherapy was an independent
predictor for disease-specific survival in patients with cancer of
the oropharynx, with a hazard ratio of 2.3. We found comparable
results in this mixed group of head and neck cancer patients, and
this finding therefore can now be extended to the entire group of
patients with head and neck cancer.
Recently, two studies investigated the impact of weight loss
during radiotherapy on survival (Pai et al, 2012; Cho et al, 2013).
In the study of Pai et al (2012), weight loss during radiotherapy
was an independent prognostic factor for locoregional control, but
not for survival. Cho et al (2013) found weight loss of X10%
during and 1 year after treatment as an independent prognostic
factor for disease-free survival (hazard ratio 2.2), but not for overall
survival, in patient with cancers of the oral cavity and oropharynx).
Our results are in line with those of Cho et al (2013). We
examined the association of critical weight loss during radiotherapy
and 5-year overall and disease-specific survival. In the unadjusted
analysis, we found that critical weight loss during radiotherapy was
significantly associated with a worse 5-year overall survival, but this
association disappeared after adjusting for other relevant prognostic
factors. However, critical weight loss during radiotherapy was an
independent prognostic factor for 5-year disease-specific survival.
The observation that patients with critical weight loss during
radiotherapy have worse disease-specific survival suggests that
treatment is less effective in this patient group. The direct effect of
radiotherapy on cancer cell death through irreparable DNA
damage is intensified by stimulating an anti-tumour immune
response (Vu et al, 2010; Kwilas et al, 2012; Tong et al, 2012). The
poor response to treatment might be due to an impaired immune
response as a consequence of insufficient food intake in the
malnourished patients. The immune system is highly dependent
upon an adequate availability of amino acids (Li et al, 2007) and
specific vitamins, minerals, and trace elements (Wintergerst et al,
2007; Mora et al, 2008). Deficiency of nutrients alters the immune
response, even when the deficiency state is relatively mild
(Chandra, 2002). We attempted to link critical weight loss and
immunity in our own series. It was previously demonstrated that a
severe deficiency of peripheral blood iNKT cells in patients with
head and neck cancer was significantly related to poor clinical
outcome, suggesting their critical contribution to anti-tumour
responses in head and neck cancer patients (Molling et al, 2007).
We post hoc analysed the relation between weight loss and iNKT
cells and found that patients with 45% weight loss had
significantly lower numbers of T cells (722±306 vs 1162±580T
cells per ml in patients withp5% weight loss, P¼ 0.021), and more
often a low (o25th percentile) iNKT cell level compared to
patients withp5% weight loss (55% vs 15% of patients, P¼ 0.004).
Although this analysis strengthened our hypothesis, further
investigation of the impact of malnutrition on immune response
in cancer patients is clearly warranted.
Weight loss during radiotherapy frequently occurs in patients
with head and neck cancer. In our study, the prevalence of critical
weight loss during and shortly after radiotherapy was 57%. Several
different definitions are used to define malnutrition or severe
weight loss (Meijers et al, 2010). Our cutoff points for critical
weight loss during radiotherapy were based on the international
consensus statement of the Academy of Nutrition and Dietetics
and the American Society for Parenteral and Enteral Nutrition
(White et al, 2012). Lower or higher cutoff points could probably
decrease or increase the hazard ratios.
Although we did not reach weight stabilisation during radio-
therapy with our nutritional policy, critical weight loss can be
avoided. Several studies in patients with head and neck cancer
showed that nutritional therapy can be effective in stabilising body
weight during radiotherapy (Isenring et al, 2004; Macia et al, 1991).
Our results may cautiously suggest that preventing malnutrition by
nutritional therapy might exert a positive influence on cause-
specific survival. However, intervention studies are needed to
answer the important question if prevention of weight loss indeed
has an impact on survival.
Most of the previous studies on the association of pre-treatment
weight loss and overall survival performed only unadjusted
analyses. The drawback of unadjusted survival analyses is that
confounders may disturb the relation between weight loss during
radiotherapy and survival. Thus, significant differences in the
unadjusted analyses may result from other confounding variables,
such as tumour location and disease stage. A strength of the
present study is that herein adequate adjustment for relevant
prognostic factors was possible.
Some limitations of this study should be acknowledged. First, we
had to exclude 172 patients (13%) for the analysis of weight loss
during radiotherapy, and these patients had a worse overall
survival compared with the included patients. It is unknown
whether the exclusion of those patients has affected our results,
that is, the absence of an association between critical weight loss
during radiotherapy and overall survival. Second, the dose
distribution of radiotherapy may influence the amount of weight
loss during radiotherapy. Given the number of patients we did not
delineate organs at risk for weight loss, but we used target volume
in general (local vs unilateral neck vs bilateral neck) as a surrogate
for dose to the swallowing structures. In another analysis
(unpublished data), we found that this provides useful information
with regard to the dose distribution to the most important organs
at risk. Third, despite the adjustment for important confounding
variables, we were not able to adjust for comorbidity in the entire
group of patients. We used the WHO performance score. In the
subgroup of patients receiving chemoradiotherapy, results of the
ACE-27 test (Paleri and Wight, 2002) were available and used for a
subanalysis. In contrast to what we expected, comorbidity did not
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Figure 3. Kaplan–Meier survival plot of disease-specific survival by
weight loss during radiotherapy (log-rank test: P¼ 0.001).
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studies, pre-treatment weight loss had to be recalled because
patients were newly referred to the hospital. We suppose that
patient might have underreported their weight loss, especially
patients with the smallest amounts of weight loss who where
therefore classified into the reference group. This might have lead
to underestimation of the prognostic effects on survival. On the
other hand, it has been demonstrated that self-reported weight is a
highly sensitive method to define malnutrition (Haverkort et al,
2012). The weight loss categories in our study had large intervals,
so small differences in weight loss estimation would not have lead
to other classification. We therefore deem that the results might
marginally be influenced by the recall method, and if so, the extent
of the association between weight loss before radiotherapy and
survival is probably underestimated.
In conclusion, weight loss both before and during radiotherapy
are important prognostic indicators for 5-year disease-specific
survival in patients with head and neck cancer. Randomised studies
into the prognostic effect of nutritional intervention during
radiotherapy are needed.
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